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BSTRACT
Background:
 
The aim of the present survey was to
investigate the changes associated with fexofenadine
administration in the quality of life (QOL) of Japanese
cedar pollinosis patients.
 
Methods:
 
After obtaining informed consent, volun-
teers suffering from Japanese cedar pollinosis were
divided into two groups: (i) the fexofenadine group
(2 
 
×
 
 60 mg/day); and (ii) the placebo group. Changes
in QOL were examined after administration for
14 days (randomized, double-blind comparison study).
The study period was from 27 February to 13 March
2003. Subjects were recruited from the Tokyo metro-
politan area; 104 were randomized to the fexofena-
dine group and 103 were randomized to the placebo
group. The QOL was evaluated using the Japanese
Allergic Rhinitis Standard QOL Questionnaire (JRQLQ
no. 1). The JRQLQ is structured to evaluate six
domains of usual daily activities, outdoor activities,
social functioning, sleep problems, general physical
problems and emotional function, as well as the
overall QOL.
 
Results:
 
On the 14th day after the start of fexofena-
dine or placebo administration, the QOL was improved
in all domains of the JRQLQ in the fexofenadine
group, whereas it had worsened in all domains, except
outdoor activities, in the placebo group. The overall
evaluation of QOL was significantly more favorable in
the fexofenadine group on the 14th day after the start
of administration.
 
Conclusions:
 
The present study showed that fexo-
fenadine administration suppressed the deterioration
of overall QOL and alleviated the interference with
daily life in patients suffering from Japanese cedar
pollinosis.
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I
 
NTRODUCTION
 
Allergic rhinitis does not threaten life directly, but it has a
significant impact on the quality of life (QOL) and
sometimes restricts the daily activity of patients. Further-
more, allergic rhinitis symptoms influence study and
work conditions, inflicting a significant burden socially
and economically. In Japan, approximately 15% of the
population nationwide suffers from cedar pollinosis.
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Many types of therapy are used for the treatment of
allergies, including pollinosis. Among the most frequently
used pharmacotherapies, antihistamines are often the
drugs of choice. Antihistamines relieve symptoms, but
they do not cure the disease. With antihistamines,
patients can spend their daily life more comfortably and
productively.
Fexofenadine HCl was approved as an antihistamine
against allergies in September 2000 in Japan and it is
currently used widely. Abroad, it has been approved in
102 countries, including the US, UK, France and
Germany, and, as of March 2000, fexofenadine HCl was
marketed in 57 countries.
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In the present study, the QOL of Japanese cedar polli-
nosis patients was evaluated, in comparison with a
placebo control, using the ‘Japanese Allergic Rhinitis
QOL Standard Questionnaire’ (JRQLQ) after administra-
tion of 60 mg fexofenadine HCl, twice daily for 14 days.
 
M
 
ETHODS
 
Patients
 
The subjects were male and female Japanese cedar
pollinosis patients (hereafter called ‘patients’) aged from
20 to 56 years. Cedar pollinosis symptoms had to have
been present for more than 2 years and cedar pollen-
specific IgE was class 2 or above. Patients who lived or
worked in the metropolitan area were favored as study
subjects. In addition, the total symptom score (TSS;
comprising sneezing, runny nose, nasal congestion, itchy
eyes and watery eyes) was at least 4 and at least two of
the five symptoms were of greater than moderate severity
on the starting day of administration.
The following patients were excluded from the study:
patients whose symptoms had developed before the
cedar pollen season, patients with complications of nasal
diseases that could have an effect on the evaluation of
efficacy (perennial allergic rhinitis, acute and chronic
rhinitis etc.), patients who planned to go to Hokkaido,
Okinawa or abroad, and others whom the physician-in-
charge judged unfit as study subjects.
Prior to participation in the present study, written
consent was obtained from all patients after the physician-
in-charge had explained the study in person to the
patients. In addition, the study was conducted with
the approval of the Institutional Review Board of Nippon
Medical School.
 
Study design
 
The present study was a randomized, double-blind
comparison study against a placebo control, performed
at a single institution.
After obtaining patient consent, screening was per-
formed to confirm compliance with the subject selection
and exclusion criteria and to examine the physical con-
dition of each individual. Screening included patient
background, physician’s examination, clinical laboratory
analysis (hematology, blood biochemistry, serology and
urinalysis), physical examination, and electrocardiogram
(12 lead electrocardiogram). The physician-in-charge
determined the eligibility of each patient as a subject in
the present study based on the results of screening. The
pre-observation period was 7 days before the start of
administration of the trial drug, during which time the
physician’s examination, rhinoscopy and blood collec-
tion were performed. Following completion of the pre-
observation period, patients were assigned at random to
receive test drug or placebo and administration was
started. A fexofenadine HCl 60 mg tablet (fexofenadine
group) or placebo tablet (placebo group) was adminis-
tered twice a day, once in the morning and once in the
evening, for 14 days (Fig. 1).
Patients were asked to record in the patient diary polli-
nosis symptoms (sneezing, runny nose, nasal congestion,
itchy eyes, watery eyes and interference with daily life)
and compliance with the drug administration schedule.
The physician-in-charge examined each patient a total
of five times: at screening, during the pre-observation
period, on the starting day of drug administration and 1
and 2 weeks after the start of drug administration. The
baseline data were those at the start of drug administra-
tion and the end-points were data obtained 2 weeks after
the start of test drug administration.
Patients were asked to fill out the JRQLQ
questionnaire
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 at the start of the pre-observation period,
on the starting day of drug administration and at the
times of hospital visits, 1 and 2 weeks after the start of
drug administration (Fig. 2). In addition, patients were
asked to make an entry in the patient diary every day from
the start of the pre-observation period until the day after
the completion of drug administration.
During the study period, any concurrent use of drugs
that could influence the evaluation of efficacy was pro-
hibited. However, when drugs had to be used, as judged
by the physician-in-charge, the drugs used were recorded
in the survey form.
 
Evaluation items
 
The JRQLQ
 
The JRQLQ, which was used as the primary standard for
evaluation, is composed of three parts: nasal and eye
symptoms (JRQLQ I), a QOL-related questionnaire
(JRQLQ II) and an overall face scale.
The nasal and eye symptoms included the six cate-
gories of runny nose, sneezing, nasal congestion, itchy
nose, itchy eyes and watery eyes. Each subject evaluated
symptoms on a five-point scale, which included 0 for no
symptoms, 1 for mild, 2 for moderately severe, 3 for
severe and 4 for very severe symptoms. Mean scores for
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these six categories were determined as the mean nasal
and eye symptom scores (JRQLQ I).
The QOL-related questionnaire included 17 items
concerning: (i) reduced productivity at work/home/
school; (ii) poor mental concentration; (iii) reduced think-
ing power; (iv) impaired reading book/paper; (v) reduced
memory loss; (vi) limitation of outdoor life (e.g. sports,
picnic); (vii) limitation of going out; (viii) hesitation visiting
friend or relatives; (ix) reduced contact with friends or
others by telephone or conversation; (x) not an easy
person to be around; (xi) impaired sleeping; (xii) tired-
ness; (xiii) fatigue; (xiv) frustration; (xv) irritability; (xvi)
depression; and (xvii) unhappiness. Each item was evalu-
ated on a five-point scale as 0 for no significant problem,
1 for a mild problem, 2 for moderately severe, 3 for
severe and 4 for very severe (Fig. 2). Mean scores
for  these categories were determined as the mean
QOL-related questionnaire scores (JRQLQ II). In addi-
tion, these categories were divided into six domains,
including ‘usual daily activities’ for items i–v, ‘outdoor
activities’ for items vi and vii, ‘social functioning’ for items
viii to x, ‘sleep problem’ for item xi, ‘general physical
problems’ for items xii and xiii, and ‘emotional function’
for items xiv to xvii. The mean score for each domain was
calculated for analysis.
Overall face scale, including overall symptoms, condi-
tion and feelings, was evaluated on a scale from 0 for
‘happy’ to 4 for ‘crying’ for the past 1–2 weeks.
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The present study evaluated the mean score for each
domain in the QOL-related questionnaire as well as
JRQLQ I, JRQLQ II and overall face scale.
 
Allergy diary
 
In the allergy diary, each item from a list including
sneezing (number of attacks in a day), runny nose
(number of incidences of nose blowing per day), nasal
congestion, itchy eyes and watery eyes was evaluated on
 
Fig. 1
 
Study design.
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a scale from 0 for the most mild to 4 for the most severe.
The total scores for sneezing, runny nose, nasal con-
gestion, itchy eyes and watery eyes were calculated as
the TSS for statistical analysis. The severity in the season
was compared between the fexofenadine and placebo
groups.
 
Safety
 
All unfavorable signs and symptoms observed during the
period of administration of the test drug were classified
as adverse events, regardless of the presence or absence
of a causal relationship to the test drug.
The safety items evaluated included analysis of data
obtained during the study period (clinical laboratory
analysis, physical examination and physician’s examina-
tion) and symptoms experienced during the study period
(only adverse events reported at the physician’s examina-
tions, but not those described in the allergy diary).
 
Statistical analysis
 
Continuous variables and categorical variables were
analyzed by the Mann–Whitney 
 
U
 
-test and Chi-squared
test, respectively, for characteristics related to patients’
background (age, sex, address, occupation and work
place).
Changes in JRQLQ scores from baseline were analyzed
by analysis of covariance (
 
ANCOVA
 
), with the treatment
group as the main effect and the baseline values as the
covariate. For TSS, the statistical significance between
two groups was examined using the Mann–Whitney
 
U
 
-test.
 
Fig. 2
 
Japanese Allergic Rhinitis Standard Quality of Life Questionnaire (JRQLQ no. 1).
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R
 
ESULTS
 
Patient population
 
Of a total of 250 subjects screened, 210 were ran-
domized to receive treatment; 104 received fexofena-
dine HCl 60 mg b.i.d. (fexofenadine group) and 103
received placebo b.i.d. (placebo group). All 207 rand-
omized subjects completed the 2 week study period.
Overall, 207 subjects were enrolled in the Intent-to-
Treat (ITT) population (patients who received at least one
dose of treatment and completed a baseline and not less
than one valid QOL assessment): 104 subjects in the
fexofenadine group and 103 in the placebo group. There
were no differences between the two treatment groups
in terms of demographic characteristics (Table 1). The
mean age of subjects in the fexofenadine group was
32.7 years compared with 34.2 years in the placebo
group. The majority of patients were male (60% fexofena-
dine group; 56% placebo group). There were almost
equal numbers of students (47% fexofenadine group;
45% placebo group) and non-students (53% fexofena-
dine group; 55% placebo group).
Baseline JRQLQ scores were comparable between the
two treatment groups (Table 2). The mean QOL-related
questionnaire score (JRQLQ II) was 1.00 in the fexofena-
dine group and 0.89 in the placebo group, showing that
patients were greatly troubled by pollinosis symptoms.
Individual JRQLQ domain scores at baseline indicated
that patients were less troubled by their symptoms in rela-
tion to their social functioning and were more troubled
in their usual daily activities, outdoor activities and by
general physical problems.
 
Table 1
 
Patient characteristics at baseline (Intent-to-Treat population)
Characteristic Fexofenadine HCl 
60 mg b.i.d 
(
 
n
 
 = 104)
Placebo 
(
 
n
 
 = 103)
 
P
 
Mean (
 
±
 
SD) age (years) 32.7 
 
± 
 
9.8 34.2 
 
± 
 
9.8 0.631*
Sex
Total 104 103
No. males (%) 62 (60) 58 (56) 0.674
 
†
 
No. females (%) 42 (40) 45 (44)
Occupation
No. students (%) 48 (47) 45 (45) 0.769
 
†
 
No. non-students (%) 55 (53) 56 (55)
 
*Wilcoxon test.
 
†
 
Chi-squared test.
 
Table 2
 
Baseline Japanese Allergic Rhinitis Standard Quality of Life Questionnaire (JRQLQ) scores (Intent-to-Treat population)
Scores Fexofenadine HCl 
60 mg b.i.d 
(
 
n
 
 = 104)
Placebo 
(
 
n
 
 = 103)
 
P
 
 (Wilcoxon test)
Nasal and eye symptoms 1.60 
 
± 
 
0.73 1.60 
 
± 
 
0.73 0.864
QOL-related questionnaire 1.00 
 
± 
 
0.86 0.89 
 
± 
 
0.73 0.557
Scores by domain
Usual daily activities 1.19 
 
± 
 
1.0 0.96 
 
± 
 
0.8 0.123
Outdoor activities 1.03 
 
± 
 
1.0 1.08 
 
± 
 
1.0 0.682
Social functioning 0.66 
 
± 
 
0.8 0.64 
 
± 
 
0.7 0.75
Sleep problem 0.93 
 
± 
 
0.9 0.83 
 
± 
 
0.9 0.285
General physical problems 1.12 
 
± 
 
1.1 0.96 
 
± 
 
1.0 0.495
Emotional function 0.96 
 
± 
 
1.0 0.87 
 
± 
 
0.9 0.993
Condition of past 1 or 2 weeks 2.46 
 
± 
 
0.9 2.45 
 
± 
 
0.9 0.961
 
Data are the mean 
 
±
 
SD.
QOL, quality of life.
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Fig. 3
 
Mean Japanese Allergic Rhinitis Standard Quality of Life Questionnaire (JRQLQ) scores at baseline (
 

 
) and at the end of
the 2 week administration period (
 

 
) for (a) placebo and (b) fexofenadine HCL 120 mg (60 mg b.i.d.).
 
Fig. 4
 
Mean changes in scores from baseline (
 

 
, nasal and eye symptoms; 
 

 
, quality of life-related questionnaire; , overall
face scale) following 2 week administration of (a) placebo or (b) fexofenadine HCL 120 mg (60 mg b.i.d.). *
 
P
 
 < 0.001 compared
with placebo.
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Outcome
 
Quality of life
 
Mean scores in each domain are shown for JRQLQ I
and JRQLQ II in Fig. 3. Scores of all domains, except
outdoor activities, decreased or worsened in the placebo
group, whereas all showed an improvement in the
fexofenadine group.
Significant improvements in scores from baseline were
clearly seen in the fexofenadine group for JRQLQ I,
JRQLQ II and the overall face scale (
 
P
 
 < 0.001; Fig. 4).
In addition, with regard to each domain of JRQLQ II, a
significant improvement in scores was observed for usual
daily activities (
 
P
 
 < 0.001), social functioning (
 
P
 
 = 0.002),
general physical problems (
 
P
 
 < 0.001) and emotional
function (
 
P
 
 = 0.002) in the fexofenadine group (Fig. 5).
Scores for outdoor activities (
 
P
 
 = 0.055) and sleep prob-
lems (
 
P
 
 = 0.064) tended to improve, albeit not signifi-
cantly, in the fexofenadine group.
In JRQLQ II by domain in each week, there was a sig-
nificant improvement in the first week for all the domains
in the fexofenadine group. No significant change was
seen in the fexofenadine group for outdoor activities
(
 
P
 
 = 0.055) and sleep problems (
 
P
 
 = 0.064) in the
second week (end-point), which could have been due to
changes in the pollen count (Fig. 6).
 
Symptom severity
 
The daily TSS (total score of sneezing, runny nose, nasal
congestion, itchy eyes and watery eyes), as calculated
from the subject diary, significantly improved in the
fexofenadine group from the first day after administra-
tion compared with the placebo group. This improve-
ment was sustained at the peak pollen count, showing
improvement every day throughout the administration
period (Fig. 7).
 
Safety
 
No serious adverse events were reported throughout the
study period. There was no significant difference in the
number of adverse events between the two groups
(
 
P
 
 = 0.568). A high white blood cell count and head-
ache occurred most frequently.
 
Fig. 5
 
Mean changes in scores from baseline (domains in the quality of life-related questionnaire) following 2 weeks administration
of placebo (
 

 
) or fexofenadine HCL 120 mg (60 mg b.i.d.; 
 

 
). Changes in nasal and eye symptoms, which are shown in Fig. 4,
are shown as a reference. **
 
P
 
 < 0.01, ***
 
P
 
 < 0.001 compared with placebo.
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Fig. 6
 
Changes in quality of life-related questionnaire domains from baseline to end-point following 2 weeks administration of
placebo (
 
) or fexofenadine HCL 120 mg (60 mg b.i.d.; ). *P < 0.05, **P < 0.01, ***P < 0.001 compared with
placebo.The starting day of administration (baseline), 1 week after the start of administration and 2 weeks after the start of admin-
istration (end-point) are indicated on the graphs as 0, 1 and 2 weeks, respectively.
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DISCUSSION
Allergic rhinitis has been regarded as a ‘life style
disease’ that interferes with daily life rather than as a
‘chronic disease’. This is based on the fact that allergic
rhinitis is not a life-threatening disease but, rather, it
worsens QOL. The World Health Organization defines
QOL as an individual’s perception of their position in
life in the context of the culture and value systems in
which they live and in relation to their goals, expecta-
tions, standards and concerns.3 To determine whether
an improvement or deterioration of QOL has taken
place, oral and written questionnaires are administered.
Among the questionnaires that are currently used main-
stream methods of surveying, some (SF-36 etc.) are not
specific to particular diseases and examine general
health status, whereas others examine QOL specific to a
disease. From a survey using SF-36, Fukuroku et al.3
reported that among nasal symptoms in perennial aller-
gic rhinitis, nasal congestion was the one that interfered
most severely with the QOL. The Juniper questionnaire is
the only one specific to allergic rhinitis and is regarded
as the standard questionnaire in the US and Europe.4
Using this questionnaire, it has been reported that there
is a correlation between the severity of disease and the
QOL score of patients.5
We have recently developed and validated a Japan-
ese original standardized questionnaire for allergic rhini-
tis.6 The findings of the present study demonstrate that
fexofenadine HCl 60 mg b.i.d. significantly improved the
overall QOL and total symptom score in Japanese sub-
jects with pollinosis compared with placebo during the
2 week treatment period. This improvement in QOL was
associated with significant symptom relief in the fexofena-
dine treatment group. Furthermore, fexofenadine-treated
subjects experienced significant improvement in nasal
and eye symptoms, usual daily activities, social function-
ing, general physical problems and emotional function.
These significant improvement scores ranged from 0.19
to 0.35 in the Rhinoconjunctivitis Quality of Life Ques-
tionnaire (RQLQ). This improvement rate is not consistent
with the Juniper theory of 0.5.7
The results presented here are consistent with those
published previously, in which fexofenadine significantly
Fig. 7 Total symptom score (TSS) in subject diary and pollen counts following 2 weeks administration of placebo () or fexofena-
dine HCL 120 mg (60 mg b.i.d.; ). The TSS included sneezing, nasal discharge, nasal congestion, itchy eyes and watery eyes. The
number of cedar pollens throughout the 2 week period is indicated by the shaded area on the graph. *P < 0.05, **P < 0.01,
***P < 0.001 compared with placebo.
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improved QOL in pollinosis and chronic indiopathic
urticaria (CIU) patients.8–11 Tanner et al. assessed the
impact of fexofenadine HCl 60 mg b.i.d. on patients’
QOL in a pooled analysis of two placebo-controlled
trials in patients with pollinosis.8 A significant (P = 0.05)
improvement in overall RQLQ score was reported for
patients receiving fexofenadine HCl 60 mg b.i.d. compared
with placebo.8 In a more recent study, van Cauwenberge
et al.11 assessed the impact of once-daily administration
of fexofenadine HCl 120 mg, loratadine 10 mg or
placebo on patients’ QOL in the treatment of pollinosis.
A total of 509 pollinosis patients aged 12–75 years com-
pleted the QOL assessment (RQLQ). For all treatment
groups (fexofenadine, loratadine and placebo), there
was a significant improvement from baseline in overall
QOL (P < 0.0001); however, the improvement in the
fexofenadine group was significantly greater than that
obtained in either the loratadine (P = 0.03 for fexofena-
dine vs loratadine) or placebo (P = 0.005 for fexofena-
dine vs placebo) groups. In addition, fexofenadine was
significantly better than either loratadine or placebo in
reducing overall mean 24 h reflective symptom scores for
itchy, watery or red eyes and nasal congestion from base-
line (P = 0.05), whereas the effect of loratadine on these
two symptom scores did not differ from that of placebo.11
Furthermore, in patients with CIU, fexofenadine HCl
60 mg b.i.d. significantly improved overall QOL com-
pared with placebo.9 These results corroborate the find-
ings presented here that fexofenadine improved overall
QOL in Japanese subjects with pollinosis.
The present clinical study demonstrated the usefulness
of the recently validated JRQLQ instruments in assessing
QOL in a Japanese patient population with pollinosis
during the peak cedar pollinosis season. The JRQLQ, as
a measure of QOL, will soon be adopted as an outcome
measure for clinical trials in the Japanese population.12
The results presented here support the use of the JRQLQ
questionnaire for assessing the impact of pollinosis symp-
toms on QOL.
Conclusions
In conclusion, the present clinical study showed that
fexofenadine HCl 60 mg b.i.d. significantly improves
QOL in Japanese patients with pollinosis during the
peak cedar pollenosis season, using a recently validated
Japanese instrument.
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